First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

• Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. Methods In a phase 3, open-label trial, we randomly assigned, in a 1:1:1:1 ratio, fit patients with CLL who did not have TP53 aberrations to receive six cycles of chemoimmunotherapy (fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab) or 12 cycles of venetoclax-rituximab, venetoclax-obinutuzumab, or venetoclax-obinutuzumab-ibrutinib. Ibrutinib was discontinued after two consecutive measurements of undetectable minimal residual disease or could be extended. The primary end points were undetectable minimal residual disease (sensitivity,

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Nyckelord

Hematology/Oncology

Leukemia/Lymphoma

Treatments in Oncology

bendamustine

cyclophosphamide

fludarabine

ibrutinib

obinutuzumab

rituximab

venetoclax

aged

alanine aminotransferase level

anemia

Article

atrial fibrillation

blood

breast disease

cancer combination chemotherapy

chronic lymphatic leukemia

connective tissue disease

controlled study

death

diarrhea

disease exacerbation

drug efficacy

drug safety

drug withdrawal

faintness

febrile neutropenia

female

fever

first-line treatment

flow cytometry

genital system disease

human

human cell

hypersensitivity

hypertension

hypophosphatemia

infection

influenza

leukocyte

leukocyte count

leukopenia

major clinical study

male

minimal residual disease

multiple cycle treatment

musculoskeletal disease

neutropenia

neutrophil count

non melanoma skin cancer

open study

phase 3 clinical trial

platelet count

pneumonia

postoperative complication

progression free survival

prospective study

randomized controlled trial

side effect

skin disease

solid tumor

thrombocytopenia

treatment response

tumor lysis syndrome

upper respiratory tract infection

urinary tract infection

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)